Fairey William 4

What Happened

• William Fairey, a director of Mirum Pharmaceuticals (MIRM), received two equity awards on 2026-06-15: 3,772 derivative share units and 1,980 deferred stock units. Both awards were granted at $0.00 (no cash paid). These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (covers the 6/15 grant).
• Award amounts and price: 3,772 derivative shares @ $0.00; 1,980 deferred stock units @ $0.00.
• Shares owned after transaction: not reported in this filing.
• Footnote F1 (3,772 award): vest on the first anniversary of the grant date; the option will in any case be fully vested by the issuer's 2027 annual stockholder meeting.
• Footnote F2 (1,980 deferred stock units): each unit equals a contingent right to one share, vests on the first anniversary of the grant date (and will be fully vested by the 2027 annual meeting); vested units are payable in common stock upon the earlier of a change in control or within 60 days after separation from service.
• Filing timeliness: filed two days after the transaction date (appears timely).

Context

• These were grants/awards (code A) for compensation/retention purposes rather than market buys or sales; they are commonly used to align director incentives and do not by themselves signal buying or selling intent.
• The derivative award appears subject to a standard vesting schedule; deferred stock units are a contingent right to receive shares under the stated vesting and payout conditions.